<DOC>
	<DOCNO>NCT02156674</DOCNO>
	<brief_summary>This single center study NaglazymeÂ® give weekly two year patient Maroteaux-Lamy syndrome , also know mucopolysaccharide VI ( MPS VI ) , previously treat allogeneic transplant .</brief_summary>
	<brief_title>Naglazyme After Allo Transplant Maroteaux-Lamy Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Mucopolysaccharidosis VI</mesh_term>
	<criteria>Mucopolysaccharidosis type VI ( MPS VI , MaroteauxLamy syndrome ) treat prior allogeneic transplant &gt; 2 year previously Persons currently receive Naglazyme may accept study Age &gt; 2 year &gt; 10 % engraft base recent test Willing commit travel University Minnesota every 6 month Written inform consent parent/guardian consent child &lt; 18 year age person unable consent minor assent appropriate History cardiac pulmonary insufficiency require continuous supplemental oxygen Pregnant breastfeed Any condition , view investigator , place patient high risk poor treatment compliance completing study</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Maroteaux-Lamy Syndrome</keyword>
	<keyword>mucopolysaccharide VI</keyword>
	<keyword>MPS VI</keyword>
</DOC>